InflaRx N.V. (IFRX) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of InflaRx N.V. $0.31, price $145, upside -99.8%, quality 21 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch InflaRx N.V. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range $0.7305 – $150.00 · fair‑value band $0.2000 – $0.3800 · the $145.00 price screens above the $0.3100 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.
Follow InflaRx in your weekly email
Every Wednesday you see whether InflaRx is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Show more
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
Stock analysis
InflaRx N.V. (IFRX) currently trades at $145.00, while our model-based Fair Value estimate is $0.3100, 99.8% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $0.2000 (bear) to $0.3800 (bull), the price of $145.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 21/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
InflaRx N.V. reported revenue of €29.3K in FY2025 versus €0 in FY2021. Reported net income was −€45.6M in FY2025.
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −100%, IFRX screens richer than that median.
Fair Value models
Bear $0.2000Fair Value $0.3100Bull $0.3800
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak, negative or inconsistent.
Revenue growth 1 year
−82.3%
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−22.7%
’17
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−8,417.7% (2017) → −164,525.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (81 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 629 stocks
Beats the industry median on 0/5 measures
Overall it trails its industry peers.
Valuation
Quality Score25 · Bottom 25%
Fair Value upside−99.8% · Bottom 25%
Profitability
Return on assets−39.1% · Bottom 25%
Growth and dividend
Revenue growth−80.8% · Bottom 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B6.42× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "InflaRx N.V. Fair Value". https://www.fairvalue-calculator.com/stock/IFRX
Frequently asked questions
Is InflaRx N.V. (IFRX) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of $0.3100 versus a price of $145.00, about −100% upside (overvalued).
What is the fair value of IFRX?
Our model-based fair value for InflaRx N.V. is $0.3100 (as of Oct 3, 2026), built from audited fundamentals. The current price: $145.00.
What is the quality score of IFRX?
InflaRx N.V. has a Quality Score of 21/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for InflaRx N.V. (IFRX)?
Our model-based price target is the fair value of $0.3100 (as of Oct 3, 2026) from 1 valuation models. Cautious scenario $0.2000, optimistic scenario $0.3800. It is a calculation from audited fundamentals, not an analyst target.
What is the InflaRx N.V. stock forecast for 2026?
Our models put fair value at $0.3100, about −100% upside versus a price of $145.00 (overvalued). Cautious scenario $0.2000, optimistic scenario $0.3800. The calculation is refreshed regularly with new filings.
What is the revenue of InflaRx N.V. (IFRX)?
InflaRx N.V. reported trailing-twelve-month revenue of about €29.3K (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of InflaRx N.V. (IFRX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For InflaRx N.V. it is $0.3100 per share (as of Oct 3, 2026), against a price of $145.00. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is InflaRx N.V. stock overvalued or undervalued in 2026?
As of Oct 3, 2026, IFRX trades above its calculated fair value: price $145.00, fair value $0.3100, a gap of about −100% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IFRX?
No. The price is what the market pays today ($145.00); the fair value is what the company's own numbers justify ($0.3100). For InflaRx N.V. the two are $144.69 per share apart. That gap is exactly why we show both numbers side by side.
How much is InflaRx N.V. worth?
The market values InflaRx N.V. at about $267M (market capitalisation, as of Oct 3, 2026). Per share that is $145.00; our models calculate a fair value of $0.3100 per share.
What do the bullish and bearish scenarios say about IFRX?
Our models span a range for InflaRx N.V.: cautious scenario $0.2000, base $0.3100, optimistic $0.3800 per share (as of Oct 3, 2026, price $145.00). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of InflaRx N.V. (IFRX)?
Balance-sheet figures for InflaRx N.V. (as of Oct 3, 2026): return on equity −79.9%. They feed the Quality Score of 21/100, which measures business quality independently of the share price.
Which stocks are comparable to InflaRx N.V.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is InflaRx N.V. stock attractive at the current price?
The data as of Oct 3, 2026: price $145.00, calculated fair value $0.3100 (−100%), Quality Score 21/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IFRX calculated?
We run InflaRx N.V. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.3100, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. InflaRx N.V. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of InflaRx N.V. (IFRX)?
The closing price on Oct 1, 2026 was $145.00. Our model-based fair value is $0.3100, about −100% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with InflaRx N.V. right now?
The price sits above even our optimistic bull case ($0.3800). The favourable scenario is already priced in. Weak quality (21/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.2000 to $0.3800) leaves room in how you read the outcome.
Key figures of InflaRx N.V.
How large is the market capitalisation of InflaRx N.V. (IFRX)?
The market capitalisation of InflaRx N.V. is $267M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of InflaRx N.V. (IFRX)?
Earnings per share at InflaRx N.V. are $−0.7400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of InflaRx N.V. (IFRX)?
The return on equity (ROE) of InflaRx N.V. is −79.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of InflaRx N.V. (IFRX)?
On an EBIT basis the return on assets of InflaRx N.V. is −52.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of InflaRx N.V. (IFRX)?
The operating margin of InflaRx N.V. is −144,770% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at InflaRx N.V. (IFRX)?
Revenue at InflaRx N.V. is growing −80.8% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does InflaRx N.V. (IFRX) generate?
The free cash flow of InflaRx N.V. is −€34.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does InflaRx N.V. (IFRX) hold?
InflaRx N.V. holds more cash than debt, €15.1M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch InflaRx N.V. in the live analysis
One click puts InflaRx N.V. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Oct 3, 2026